Cognizant claims that Infosys used proprietary information from TriZetto's QNXT and Facets products to develop its own competing platform Infosys has reiterated its allegations against the US-listed Cognizant, calling its claims of trade secrets too vague in a case related to the latter's healthcare software, TriZetto. Both companies have sued each other in the US. Cognizant claims that Infosys used proprietary information from TriZetto's QNXT and Facets products to develop its own competing platform. Meanwhile, Infosys countersued Cognizant, accusing it of engaging in anti-competitive practices. In a Dallas court filing on February 7, Cognizant had alleged that Infosys was caught "red-handed misappropriating TriZetto trade secrets." According to Mint , Infosys responded to the allegation on February 28. "The first six-plus pages of Cognizant's response are non-responsive background information about the Facets and QNXT software that reads like a marketing piece interspersed with legal argument," the IT giant said in its reply, according to the report. Infosys accused Cognizant of contradicting itself on the confidentiality of certain documents. The company stated that initially, Cognizant had marked the documents as "highly confidential" but later withdrew this designation, allowing Infosys to file them publicly. Infosys also pointed out that Cognizant had failed to identify any specific test cases related to the allegedly stolen trade secrets, which Infosys deemed crucial for the court to determine whether any misappropriation had occurred. Earlier, Infosys had told the court that the information in question was publicly available. However, Cognizant claimed that Infosys had unauthorised access to confidential data through non-disclosure and access agreements (NDAAs). BY Outlook Business Desk Race to Become No. 2 in IT Services The legal battle in the US comes at a time when Infosys and Cognizant are competing to secure the second spot in India's IT services market, behind Tata Consultancy Services Ltd. Infosys reported $4.94 billion in revenue for the December quarter, whereas Cognizant earned $5.08 billion in quarterly revenue during the same period. During the third quarter earnings call, Cognizant CEO Ravi Kumar noted that health sciences brought over 10% revenue growth for the firm. "This included continued strength in TriZetto, our differentiated software platform that is used to process about two-thirds of US healthcare claims. As a recent example, we entered an agreement in 2024 to enhance healthcare operations for Blue Shield of California with our TriZetto Facets platform as a service solution," he said.